# Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

> **NCT05457946** · PHASE2,PHASE3 · UNKNOWN · sponsor: **LG Chem** · enrollment: 1438 (estimated)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type B Infection

## Interventions

- **BIOLOGICAL:** LBVD (Hexavalent vaccine)
- **BIOLOGICAL:** Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)

## Key facts

- **NCT ID:** NCT05457946
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 1438 (ESTIMATED)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457946, "Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05457946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*